AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
7747.T

Asahi Intecc Co., Ltd. (7747.T) fair value

Healthcare · Medical Instruments & Supplies · TSE · Japan
¥3698.00-1.26%
Market cap ¥981.2BNext earnings 2026-11-13Updated Oct 24, 2026 · valuation updating
Our verdict
No fair value
We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: there are no financial statements on file yet.
ACCE opinionAsahi Intecc Co., Ltd. (7747.T)
Fair value
Not available
ACCE price target
¥3180
Rating
Not rated
Horizon
12 months
ACCE price target published on 23 Oct 2026, 01:53 CEST.
Price used: ¥3698 at the close on 23 Oct 2026, 08:30 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
79
out of 100
P/E
30.4x
forward 46.5x
1-year return
+50.5%
Dividend yield
1.33%

Asahi Intecc Co., Ltd. in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Asahi Intecc makes guidewires, microcatheters and other disposable devices used in interventional cardiology and peripheral vascular procedures, with its Gaia and Sion guidewire families among the core products in catheter labs. Its edge is a high gross margin of 70.4% and a long record of niche device design that interventionalists are slow to switch away from once a product is trusted in the cath lab. Revenue growth of 31.3% is the number that stands out, and the forward P/E of 47.1 against a trailing 31.3 implies the market expects earnings to be dampened ahead, so the reader should check whether that reflects a known pricing, reimbursement or competitive issue. At a 20.6% operating margin and 19.7% ROE, the business is clearly profitable, but the valuation leaves little room for a margin or growth miss, which makes this worth a deeper look at the next earnings disclosure and the company's guidance.

AI-assisted·How I use AIWritten Oct 23, 2026

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where 7747.T's valuation models land
Price
¥3698.00
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
+5.7%
1 month
+12.9%
3 months
+9.4%
6 months
+10.2%
YTD
+25.9%
1 year
+50.5%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 01:53 CESTACCE price target¥3180first publication¥3745

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in JPY. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full 7747.T page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth100Value34Quality91Momentum90Total79
Valuation
Trailing P/E
30.4x
Forward P/E
46.5x
PEG
0.79
P/B
no data
EV / Revenue
no data
Book value/sh
no data
Enterprise value
no data
Profitability
ROE
19.7%
FCF yield
2.44%
ROIC
no data
Health and risk
Debt / equity
0.04
Dividend yield
1.33%
Beta
no data

Price

+50.4% · 1Y

Ask anything about 7747.T

Answered from Asahi Intecc Co., Ltd. fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 60% of peers
low 0.0x30.4xhigh 49.0x
ROEbetter than 83% of peers
low -3%20%high 31%
Div yieldbetter than 83% of peers
low 0.0%1.3%high 3.1%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
7747.T Asahi Intecc Co., Ltd.¥3698.00--30.4x19.7%9179
BLCO Bausch + Lomb Corporation Common Shares$17.43----2.5%4350
CTEC.L Convatec Group PLC£2.44£21% above49.0x7.6%5550
YPSN.SW Ypsomed Holding AGCHF 387.40CHF 21977% above23.8x31.1%9267
TFX Teleflex Incorporated Common Stock$136.58$1314% above--0.7%4351
MMSI Merit Medical Systems Inc. Common Stock$93.94$5961% above38.4x9.2%6366
STVN Stevanato Group S.p.A. Ordinary Shares$19.50$1257% above34.2x9.1%6347

Sector report card

Where 7747.T ranks against its sector peers on each metric.

Computing percentiles…